Plain-English translation of NCT06549465 on ClinicalTrials.gov ↗ ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new treatment called rosopatamab tetraxetan, a radioactive antibody designed to seek out and destroy prostate cancer cells. The medication is combined with a radioactive material (Actinium-225) that delivers radiation directly to cancer lesions. Researchers want to find the safest and most effective dose of this treatment for men whose prostate cancer has stopped responding to standard hormone-blocking drugs.
Standard treatments for advanced prostate cancer eventually stop working, leaving patients with limited options. This medication is designed to target cancer cells more directly and precisely by using a radioactive component, offering a potentially new way to treat men whose cancer has become resistant to current therapies.
You likely qualify if…
You likely don't qualify if…
The study has three phases. First, you would receive a diagnostic injection to map how the medication travels in your body. Depending on your prior treatments, you would then either receive the treatment medication at one of two doses (given as two injections two weeks apart) or be enrolled in a dose-escalation phase if you've had a specific prior therapy. Throughout the study, you would attend regular clinic visits for blood tests, heart monitoring (ECG), imaging scans, and physical exams to track how you respond and monitor for any side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States